Shingles Vaccine May Help Reduce Dementia Risk, Landmark Study Finds
A major new study out of Wales has revealed a compelling link between shingles vaccine and a reduced risk of dementia. Published in Nature and based on data from over 280,000 individuals, the study found that older adults who received the shingles vaccine were 20% less likely to develop dementia over the following seven years compared to those who did not.
This research adds weight to growing evidence that viral infections—especially herpes viruses—may play a role in dementia development, and that vaccination could offer some protection.
Key Findings From the Welsh Study
Researchers took advantage of a natural policy split in Wales’ 2013 shingles vaccine rollout. Due to eligibility rules based on age, individuals who were 79 on September 1, 2013, qualified for vaccination, while those just a few days older did not. This setup allowed for a quasi-randomized comparison across similar age groups.
Key takeaways:
- People who received the vaccine were 3.5% less likely to develop dementia overall.
- When comparing those closest in age across the eligibility cutoff, the risk was reduced by 20%.
- These findings held even after adjusting for education, chronic illness, and other lifestyle factors.
Why Might a Shingles Vaccine Protect Against Dementia?
Researchers point to two potential biological mechanisms:
1. Suppression of Reactivated Varicella-Zoster Virus
- The virus that causes chickenpox (and later shingles) can stay dormant in the body for decades.
- Reactivation can lead to long-term inflammation and brain changes similar to Alzheimer’s disease.
2. Broader Immune System Boost
- The vaccine may trigger a more generalized immune response, enhancing the body’s ability to fend off inflammation or infections linked to neurodegeneration.
Neurologists such as Dr. Tissa Wijeratne view this as part of a growing understanding of how latent viruses affect brain health over time.
Are All Shingles Vaccines the Same?
The study focused on Zostavax, a live attenuated vaccine commonly used in Wales during the research period. However, many countries, including Canada, the U.S., and the U.K., now use Shingrix, a more effective, non-live recombinant vaccine.
Early evidence from other studies suggests Shingrix may offer even greater dementia risk reduction than Zostavax. More research is underway to verify this.
Sex Differences in Protection
Interestingly, the study found that women seemed to benefit more from the vaccine than men. This aligns with prior studies suggesting stronger immune responses in women, although the reasons behind this are not yet fully understood.
What This Means for Public Health
If confirmed by future research, this study could reshape how we think about dementia prevention. While there’s still no cure, experts already recommend:
- Managing blood pressure and blood sugar
- Staying socially and mentally engaged
- Maintaining regular physical activity
Now, vaccination—particularly for shingles—may soon join that list.
As Dr. Henry Brodaty of UNSW noted, “This is the best evidence yet to show that older adults who stay up-to-date with vaccinations may also be lowering their dementia risk.”
The Welsh study offers strong evidence that the shingles vaccine may do more than prevent a painful rash—it might also help protect the brain. With the aging global population and rising rates of dementia, these findings highlight the potential for vaccines to play a broader role in brain health and disease prevention.
Further clinical trials are needed, especially with newer vaccines like Shingrix. But the data so far suggest that keeping up with recommended vaccinations could have long-term cognitive benefits.
More…
